Lisata Therapeutics
LSTA
21 hedge funds and large institutions have $1.93M invested in Lisata Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5% more funds holding
Funds holding: 20 → 21 (+1)
0.64% less ownership
Funds ownership: 9.08% → 8.44% (-0.64%)
14% less capital invested
Capital invested by funds: $2.26M → $1.93M (-$324K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$59.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41K |
| 3 |
Renaissance Technologies
New York
|
+$34.6K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$251K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20.5K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$12.2K |
| 4 |
Morgan Stanley
New York
|
-$40 |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$17 |
LSTA Hedge Fund Activity: Q3 2025 in Review
21 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2025, worth a combined $1.93M — down 14% from $2.26M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LSTA positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Ground Swell Capital, opening a new position worth an estimated $59.6K. The largest seller was BML Capital Management, cutting an estimated $251K.
- 21 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2025, up from 20 in Q2 2025.
- Funds reported $1.93M of Lisata Therapeutics stock for Q3 2025, down 14% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q3 2025 and 2 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q3 2025 was Ground Swell Capital, an estimated $59.6K added.
- The largest Lisata Therapeutics seller in Q3 2025 was BML Capital Management, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2025.